HCPLive Network
  • Discussing the Flu Epidemic
  • 2015 AGA
  • Internal Medicine World Report
  • Multiple Sclerosis Peer Exchange Video Series
  • Cardiology Review
  • Physician’s Money Digest
  • HIV Peer Exchange
Latest Specialty Headlines
Thursday, January 29, 2015
By Amy Jacob
Bristol-Myers Squibb announced today the US Food and Drug Administration (FDA), had granted approval for Evotaz tablets in combination with other antiretroviral agents for an innovative treatment option for adults suffering from HIV-1 infection – delivering proven suppression through 48 weeks.
Thursday, January 29, 2015
Researchers have found that menopause typically begins 2 to 4 years earlier in women with high levels of certain chemicals found in household items, personal care products, plastics, and the environment, compared to women with lower levels of the chemicals. The study was published online Jan. 28 in PLOS ONE.
Thursday, January 29, 2015
By Amy Jacob
Hair loss, whether partial or close to baldness, is a condition that is frequently associated with feelings of poor self-confidence (even depression in severe cases) across all demographics of affected patients.
Thursday, January 29, 2015
Teledermoscopy is feasible and effective for short-term monitoring of clinically atypical nevi, according to a study published online Jan. 28 in JAMA Dermatology.
Thursday, January 29, 2015
A decision rule based on assessment of cerebrovascular reserve seems to be cost-effective for prevention of stroke in asymptomatic patients with carotid artery stenosis, according to a study published in the February issue of Radiology.
Thursday, January 29, 2015
For older adults, elevated amyloid-β (Aβ) levels correlate with cognitive decline, and elevated anxiety moderates these associations, according to a study published online Jan. 28 in JAMA Psychiatry.
Thursday, January 29, 2015
By Gale Scott
Implantable cardioverter-defibrillators (ICDs) have prevented cardiac arrests and deaths, but they carry a risk of giving patients shocks when they don’t need them. That inappropriate shock rate has been estimated as occurring in 10 to 20% of patients with the devices, causing unnecessary hospital admissions, and a negative impact on patients’ quality of life. They are also associated with increased morbidity and mortality for some patients. But in a study in Heart Rhythm Angelo Auricchio, MD, PhD, and colleagues report on technological improvements in a Medtronic device that has reduced those shocks to 1.5% with a dual/triple chamber defibrillator and 2.5% for a single chamber ICD after one year.
Thursday, January 29, 2015
By Jared Kaltwasser
Just 3 days before the state hosts the nation’s biggest sporting event, public health officials in Arizona are locked in an off-the-field battle with a different kind of opponent.
Thursday, January 29, 2015
Phosphodiesterase type 5 inhibitor use after radical prostatectomy is associated with increased risk of biochemical recurrence, according to a study published in the February issue of The Journal of Urology.
Thursday, January 29, 2015
For women with gestational diabetes mellitus (GDM), triglycerides are significantly elevated throughout pregnancy, according to a review published online Jan. 22 in BJOG: An International Journal of Obstetrics & Gynaecology.
Thursday, January 29, 2015
From 2002 to 2011 there was a decrease in the rate of hospitalizations for hepatitis A, according to a study published in the February issue of Hepatology.
Thursday, January 29, 2015
By Amy Jacob
Corticosteroid (steroid) is associated with an approximately 5-fold increase of venous thromboembolism in patients suffering from inflammatory bowel disease (IBD), according to a new study published in Clinical Gastroenterology and Hepatology.
Email Signup
Breaking News
The US Food and Drug Administration (FDA) has approved a polypill for hypertension, a combination of perindopril arginine and amlodipine (Prestalia/ Symplmed Pharma-Servier).
The US Food and Drug Administration approved ferric pyrophosphate citrate (Triferic/Rockwell) for use as an iron replacement therapy in patients with end-stage renal disease, the company announced. It is also indicated for chronic kidney disease. The drug is for adults.
The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx/Novartis) for adults with moderate to severe plaque psoriasis. The European Commission approved the same drug on Jan. 19. Its active ingredient is an antibody that binds to interleukin-17A and interferes with inflammation. The binding prevents that protein from triggering the inflammatory response that results in psoriasis patches.
Physician's Money Digest
Medical patients sometimes hear what we say skeptically, but Americans in general will believe any darn thing.
Some brokerages receive "order flow payments" in exchange for routing trades to certain exchanges. This practice is a major money-maker for brokers, but some worry it comes at the expense of clients.
Product News
Bristol-Myers Squibb announced today the US Food and Drug Administration (FDA), had granted approval for Evotaz tablets in combination with other antiretroviral agents for an innovative treatment option for adults suffering from HIV-1 infection – delivering proven suppression through 48 weeks.
The US Food and Drug Administration approved the first generic version of AstraZeneca's heartburn blockbuster, Nexium.
The US Food and Drug Administration (FDA) has approved a polypill for hypertension, a combination of perindopril arginine and amlodipine (Prestalia/ Symplmed Pharma-Servier).
HCPLive Poll
Twitter Advice
Have you ever given medical or financial advice on Twitter?